EMJ recently spoke to Claire Harrison, Professor of Myeloproliferative Neoplasms and Clinical Director at Guy’s and St Thomas’ NHS Foundation Trust, UK, following her receipt of the European Hematology Association (EHA) 2026 Lifetime Achievement Award.
She reflects on her pioneering work in myeloproliferative neoplasms (MPN), including the landmark COMFORT-II trial and the impact of Janus kinase inhibitors on patients with myelofibrosis. Harrison also explores the latest advances in MPN treatment, from emerging targeted therapies and novel approaches to disease modification to the importance of reducing thrombosis and disease progression. She discusses the vital role of patient organisations in shaping research and care, and shares her vision for the future of MPNs, including the possibility of achieving cure or minimal disease for patients.
Stay at the forefront of haematology and keep up with the latest advancements, key clinical trial results, and in-depth coverage of the Congress by subscribing to our upcoming issue of EMJ Hematology.
Read Harrison’s full interview with EMJ here.
